Related Experiment Video
Updated: Apr 3, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia
Katja Seipel1, Miguel Teixera Marques2, Marie-Ange Bozzini2
1Department of Clinical Research, University and University Hospital of Berne, Berne, Switzerland. Department of Medical Oncology, University and University Hospital of Berne, Berne, Switzerland.
Purpose:
In acute myeloid leukemia (AML), the transcription factors CEBPA and KLF4 as well as the universal tumor suppressor p53 are frequently deregulated. Here, we investigated the extent of dysregulation, the molecular interactions, and the mechanisms involved.
Experimental Design:
One hundred ten AML patient samples were analyzed for protein levels of CEBPA, KLF4, p53, and p53 modulators. Regulation of CEBPA gene expression by KLF4 and p53 or by chemical p53 activators was characterized in AML cell lines.
Results:
We found that CEBPA gene transcription can be directly activated by p53 and KLF4, suggesting a p53-KLF4-CEBPA axis. In AML patient cells, we observed a prominent loss of p53 function and concomitant reduction of KLF4 and CEBPA protein levels. Assessment of cellular p53 modulator proteins indicated that p53 inactivation in leukemic cells correlated with elevated levels of the nuclear export protein XPO1/CRM1 and increase of the p53 inhibitors MDM2 and CUL9/PARC in the cytoplasm. Finally, restoring p53 function following treatment with cytotoxic chemotherapy compounds and p53 restoring non-genotoxic agents induced CEBPA gene expression, myeloid differentiation, and cell-cycle arrest in AML cells.
Conclusions:
The p53-KLF4-CEBPA axis is deregulated in AML but can be functionally restored by conventional chemotherapy and novel p53 activating treatments.
Insights
The p53-KLF4-CEBPA axis is disrupted in acute myeloid leukemia (AML). Restoring p53 function via chemotherapy or novel treatments reactivates this axis, promoting myeloid differentiation and cell-cycle arrest in AML cells.
Area of Science:
- Hematology
- Molecular Biology
- Cancer Research
Background:
- Acute myeloid leukemia (AML) is characterized by frequent deregulation of key transcription factors and tumor suppressors.
- CEBPA, KLF4, and p53 play critical roles in normal hematopoiesis and are often dysregulated in AML.
Purpose of the Study:
- To investigate the extent of CEBPA, KLF4, and p53 dysregulation in AML.
- To elucidate the molecular interactions and mechanisms underlying this deregulation.
- To explore the potential for therapeutic restoration of the p53-KLF4-CEBPA axis.
Main Methods:
- Analysis of protein levels of CEBPA, KLF4, p53, and their modulators in 110 AML patient samples.
- Characterization of CEBPA gene expression regulation by KLF4 and p53 in AML cell lines.
- Assessment of p53 function restoration using chemotherapy and p53-activating agents.
Main Results:
- A direct regulatory axis (p53-KLF4-CEBPA) was identified, where p53 and KLF4 activate CEBPA transcription.
- AML patient cells exhibited loss of p53 function, reduced KLF4 and CEBPA protein levels, and elevated levels of p53 inhibitors (MDM2, CUL9/PARC) and nuclear export protein (XPO1/CRM1).
- Restoration of p53 function induced CEBPA expression, myeloid differentiation, and cell-cycle arrest in AML cells.
Conclusions:
- The p53-KLF4-CEBPA axis is significantly deregulated in AML.
- Therapeutic strategies targeting p53 restoration, including conventional chemotherapy and novel p53-activating treatments, can reactivate this axis.
- Restoring the p53-KLF4-CEBPA axis holds promise for AML treatment by inducing differentiation and cell-cycle arrest.
Related Concept Videos
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules

